Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a...
October 28, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025

BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...
October 07, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...
September 30, 2025 07:08 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina...
September 30, 2025 06:21 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 ...
September 08, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ to Host Investor Day on September 30, 2025

Company to highlight ongoing AXPAXLI™ wet AMD registrational program, strategy and next steps in NPDR and DME, and global commercial opportunity for AXPAXLI Event to feature global retinal disease...
August 27, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences

BEDFORD, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...
August 12, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR

BEDFORD, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...
August 05, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights

Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and...
July 29, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025

BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that...